Using immune responses to treat Leukemia

Medicine

PhD defence ceremony

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are myeloid malignancies with a poor prognosis. Allogenic hematopoietic stem-cell transplantation (HSCT) is often used to treat these conditions, to induce a graft versus leukemia immune response. However, this is a high-risk therapy with many complications. Marijn Gillissen studies the role of B cells in GvL immune responses, with the aim of increasing our understanding of these immune responses and developing less harmful, more effective therapies.

M.A. Gillissen: Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy: B Lymphocytes versus Leukemia.

Supervisor

Prof. H. Spits

Co-supervisor

Dr M.D. Hazenberg

Entrance

This event is open to the public.

Published by  University of Amsterdam